Close Menu

NEW YORK (GenomeWeb) – Meridian Bioscience said after the close of the market on Monday that its preliminary fiscal first quarter revenues are expected to be down about 2 percent year over year.

For fiscal Q1 2019, the company said that revenues are anticipated to be in the range of $51 million to $51.5 million compared to $52.3 million a year ago. The analysts' average estimate is $53.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.